Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRBU Stock Forecast 2026-2027
$1.60
Current Price
$158.19M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRBU Price Targets
+1,906.3%
To High Target of $32.00
+527.0%
To Median Target of $10.00
+150.8%
To Low Target of $4.00
CRBU Price Momentum
-16.7%
1 Week Change
-25.2%
1 Month Change
+44.1%
1 Year Change
+0.6%
Year-to-Date Change
-54.9%
From 52W High of $3.54
+53.4%
From 52W Low of $1.04
📊 TOP ANALYST CALLS
Did CRBU Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Caribou Biosciences is one of their latest high-conviction picks.
Latest CRBU Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CRBU has a bullish consensus with a median price target of $10.00 (ranging from $4.00 to $32.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $1.60, the median forecast implies a 527.0% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRBU Analyst Ratings
7
Buy
0
Hold
0
Sell
CRBU Price Target Range
Low
$4.00
Average
$10.00
High
$32.00
Current: $1.60
Latest CRBU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRBU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $11.00 |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 9, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Feb 2, 2026 | Clear Street | Buy | Initiates | $N/A | |
| Nov 5, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 3, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Apr 28, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 7, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Nov 26, 2024 | Citigroup | Buy | Maintains | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2024 | RBC Capital | Outperform | Reiterates | $N/A | |
| Jul 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 4, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 16, 2024 | Truist Securities | Buy | Maintains | $N/A | |
| May 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 19, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 12, 2024 | RBC Capital | Outperform | Reiterates | $N/A |
Caribou Biosciences, Inc. (CRBU) Competitors
The following stocks are similar to Caribou Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Caribou Biosciences, Inc. (CRBU) Financial Data
Caribou Biosciences, Inc. has a market capitalization of $158.19M with a P/E ratio of -1.0x. The company generates $11.20M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +1.9% quarter-over-quarter, while maintaining an operating margin of -1,096.4% and return on equity of -83.5%.
Valuation Metrics
Market Cap
$158.19M
Enterprise Value
$73.96M
P/E Ratio
-1.0x
PEG Ratio
0.0x
Price/Sales
14.7x
Growth & Margins
Revenue Growth (YoY)
+1.9%
Gross Margin
N/A
Operating Margin
-1,096.4%
Net Margin
0.0%
EPS Growth
+1.9%
Financial Health
Cash/Price Ratio
+74.4%
Current Ratio
6.2x
Debt/Equity
26.4x
ROE
-83.5%
ROA
-34.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Caribou Biosciences, Inc. (CRBU) Business Model
About Caribou Biosciences, Inc.
What They Do
Develops innovative genome-editing technologies.
Business Model
Caribou Biosciences generates revenue by developing therapeutic solutions using CRISPR-based gene-editing platforms. The company collaborates with academic institutions and industry leaders to translate genomic research into medical therapies, particularly focusing on oncology and immunology.
Additional Information
Caribou is positioned as a key player in the biotechnology sector, emphasizing its commitment to scientific excellence and personalized medicine. Its advancements in genetic therapies underscore its influence in the emerging field of genome manipulation, making it a significant entity in bioengineering and therapeutic interventions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
97
CEO
Dr. Rachel E. Haurwitz Ph.D.
Country
United States
IPO Year
N/A
Website
cariboubio.comCaribou Biosciences, Inc. (CRBU) Latest News & Analysis
Latest News
Quick Summary
CB-011 showed an 83% complete response rate and 91% MRD negativity in BCMA-naïve patients with r/r MM after a single dose, with durability observed at 15 months.
Why It Matters
High response rates in a challenging patient population for CB-011 indicate strong potential for market competitiveness, possibly boosting stock value and investor interest in the biotech firm.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vispa-cel showed an 82% overall response rate and 67% complete response rate in 2L LBCL patients, with a median progression-free survival of 17.1 months, and has a favorable safety profile for outpatient use.
Why It Matters
Positive results from vispa-cel in LBCL patients indicate strong efficacy and safety, potentially leading to broader adoption and revenue growth for the company involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Caribou Biosciences (NASDAQ: CRBU) is progressing its CRISPR-based CAR T cell therapies, with lymphoma candidate vispa-cel now "pivotal-ready" and CB-011 in Phase 1 for multiple myeloma.
Why It Matters
Caribou Biosciences' progress on pivotal lymphoma therapy and ongoing myeloma program enhances its growth potential, signaling possible future revenue and impact on stock performance.
Source: MarketBeat
Market Sentiment:
Neutral
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
8 days ago
Quick Summary
Caribou Biosciences, Inc. (CRBU) presented at the Jefferies Global Healthcare Conference, highlighting its innovations and strategies in the biotech sector.
Why It Matters
Caribou Biosciences’ presentation at a major healthcare conference signals potential insights into its pipeline and market strategies, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Caribou Biosciences, Inc. (Nasdaq: CRBU) CEO Rachel Haurwitz will speak at the Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 PM ET in New York.
Why It Matters
Caribou Biosciences' participation in a major healthcare conference could signal potential investor interest, insights into pipeline developments, and market positioning in CRISPR technology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
29 days ago
Quick Summary
Caribou Biosciences, Inc. (CRBU) presented at the Bank of America Global Healthcare Conference, showcasing its developments and strategies in the biotech sector.
Why It Matters
Caribou Biosciences' presentation at a major conference signals potential developments in its pipeline, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CRBU Stock
What is Caribou Biosciences, Inc.'s (CRBU) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Caribou Biosciences, Inc. (CRBU) has a median price target of $10.00. The highest price target is $32.00 and the lowest is $4.00.
Is CRBU stock a good investment in 2026?
According to current analyst ratings, CRBU has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRBU stock?
Wall Street analysts predict CRBU stock could reach $10.00 in the next 12 months. This represents a 527.0% increase from the current price of $1.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Caribou Biosciences, Inc.'s business model?
Caribou Biosciences generates revenue by developing therapeutic solutions using CRISPR-based gene-editing platforms. The company collaborates with academic institutions and industry leaders to translate genomic research into medical therapies, particularly focusing on oncology and immunology.
What is the highest forecasted price for CRBU Caribou Biosciences, Inc.?
The highest price target for CRBU is $32.00 from at , which represents a 1,906.3% increase from the current price of $1.60.
What is the lowest forecasted price for CRBU Caribou Biosciences, Inc.?
The lowest price target for CRBU is $4.00 from at , which represents a 150.8% increase from the current price of $1.60.
What is the overall CRBU consensus from analysts for Caribou Biosciences, Inc.?
The overall analyst consensus for CRBU is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are CRBU stock price projections?
Stock price projections, including those for Caribou Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 6:10 AM UTC